Mylan Attacks Newly Issued Oracea Patent

Law360, New York (October 20, 2010, 2:40 PM EDT) -- Mylan Pharmaceuticals Inc. has sued Galderma Laboratories Inc. in an effort to invalidate the drugmaker's newly issued patent related to rosacea treatment Oracea, marking the latest development in the companies' battle over a generic version of the blockbuster drug.

Mylan's complaint, lodged Monday in the U.S. District Court for the District of Delaware, seeks a judgment that a patent issued in July, referred to as the Chang patent, is invalid and that Mylan’s contemplated manufacture of a generic rosacea drug would not infringe it.

The patent...
To view the full article, register now.